This study examined changes in cardiometabolic biomarkers one year after direct acting antiviral therapy for hepatitis C virus co-infection among people with HIV. The research compared individuals with HIV who initiated direct acting antiviral (DAA) therapy with those who did not, focusing on haemoglobin A1c (HbA1c), total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL) and atherosclerotic cardiovascular disease (ASCVD) risk score. The study included people with HIV age ≥ 18 years, on antiretroviral therapy, from the NA-ACCORD and Mass General Brigham HIV cohorts. Individuals with detectable plasma HCV RNA were identified as having HCV co-infection.
Multivariable linear regression models were used to estimate HbA1c, TC, and ASCVD risk score at 12-months, comparing DAA initiators to non-initiators. The analysis involved 2374 individuals for HbA1c, 3418 for TC, and 488 for ASCVD risk score.
Results indicated no significant difference in the mean HbA1c at 12-months between DAA initiators and non-initiators. However, the mean TC was 13 mg/dL higher in DAA initiators, primarily due to increases in LDL. There was no significant difference in the mean ASCVD risk score at 12-months when comparing DAA initiators with those who did not initiate DAAs.
The study concluded that people with HIV with HCV who initiated DAA demonstrated no statistically significant difference in HbA1c or ASCVD risk score at 12-months compared to HIV/HCV co-infected persons who did no initiate DAA. TC and LDL levels increased 12 months following DAA treatment.